Advancing Brain Organoids from Research Models to Scalable Platforms

In this GEN webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year.

The post Advancing Brain Organoids from Research Models to Scalable Platforms appeared first on GEN - Genetic Engineering and Biotechnology News.